Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Research and Development
$199 Mil (TTM As of Mar. 2014)

This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Mar. 2014 was $61 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2014 was $199 Mil.


Definition

This is the expense the company spent on research and development.

Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2014 was 29.299 (Jun. 2013 ) + 49.009 (Sep. 2013 ) + 59.51 (Dec. 2013 ) + 61.3 (Mar. 2014 ) = $199 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Research & Development 6888951189310715817579157

Valeant Pharmaceuticals International Inc Quarterly Data

Dec11Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14
Research & Development 122222219202429496061
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide